Home › Non-Hodgkin Lymphoma › NCT06116110
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
RecruitingObservational study
A Prospective, Observational, Long-term Follow-up Study for Subjects Who Previously Received Zamtocabtagene Autoleucel in a North American Miltenyi Biomedicine-Sponsored Clinical Study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up. * Provided written informed consent to participate in this study. Exclusion Criteria: * None
About the study
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
What is being tested
- Long-term Follow-Up (other)
Sponsor: Miltenyi Biomedicine GmbH · Participants: 150 · Started: May 15, 2024
Contact the study team
- Sadie Swift · Phone: 617-218-0044
- Paris Jamiel · Phone: 617-218-0044
Official record on ClinicalTrials.gov — NCT06116110
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.